Re: Interferon: The magic bullet to prevent hepatocellular carcinoma recurrence after resection? [1]

Annals of Surgery

Volumn 247, Issue 5, 2008, Pages 900-

  Sun, Hui Chuan ^a   Zhang, Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; HEPATITIS B(E) ANTIGEN; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

CANCER RECURRENCE; CANCER SURGERY; DRUG EFFECT; DRUG MECHANISM; HEPATITIS B; HEPATITIS C; HUMAN; LETTER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; VIRUS TRANSMISSION; ADJUVANT THERAPY; CANCER STAGING; VIRUS INFECTION; LIVER TUMOR; NOTE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; INTERFERON ALFA-2B; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 42549151037     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31816ff75c     Document Type: Letter

References (14)

1. Clavien P-A. Interferon. The magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg. 2007;245:843-845.
2. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228-232.
3. Yamaji K, Nabeshima S, Murata M, et al. Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment. Cancer Immunol Immunother. 2006;55:394-403.
4. Matsumoto K, Okano J, Murawaki Y. Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol. 2005;40:722-732.
5. Ogasawara S, Yano H, Momosaki S, et al. Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo. J Interferon Cytokine Res. 2007;27:507-516.
6. Damdinsuren B, Nagano H, Sakon M, et al. Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol. 2003;10:1184-1190.
7. Murata M, Nabeshima S, Kikuchi K, et al. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine. 2006;33:121-128.
8. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543-1554.
9. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Intern Med. 2001;134:963-967.
10. Kubo S, Hirohashi K, Yamazaki O, et al. Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. World J Surg. 2002;26:555-560.
11. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99-111.
12. van Zonneveld M, Zondervan PE, Cakaloglu Y, et al. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006;26:399-405.
13. Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007;245:831-842.
14. Qian YB, Zhang JB, Wu WZ, et al. P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer. 2006;107:1562-1569.